Overview of China's Market Approval Policy Med Insurance Payment System
Rare disease patients in China face many challenges. Rare diseases can be challenging to diagnose. Even when patients are diagnosed, they cannot get access to efficacious treatment as there are no available drugs in China, or the approved drugs are not intended for rare disease treatments. Moreover, patients cannot afford approved drugs due to their lack of reimbursement coverage. Among them, inaccessibility and unaffordability are the most prominent causes, making more than half of patients unable to receive timely and sufficient treatment.
In this whitepaper, hear from Parexel rare disease consultants on the following topics:
- Relevant Policies on Expedited Approval of Rare Disease Drugs
- An Overview of China’s Multi-Layered Reimbursement System for Rare Disease Drugs
Related Insights
Blog
Unpacking NICE’s review of the HST routing criteria: implications for manufacturers
Oct 3, 2024
Blog
Accelerating Delivery and Patient Access to Rare Disease Treatments – Highlights from World Orphan Drug Congress
May 2, 2024
Podcast
Why Rare Disease Therapeutics Need Early Market Access Planning
Jan 4, 2023
Webinar
China's Market Approval Policy and Medical Insurance Payment System for Rare Disease
Jul 21, 2022
Report
New Medicines, Novel Insights: Advancing rare disease drug development
May 22, 2023
Article
How biotechs can strengthen their value story with advanced analytics
Feb 15, 2022
Blog
Pragmatic Trials: Targeting evidence generation to inform market access and meet payers’ needs
Feb 8, 2022
Blog
Parexel names first Patient Ambassador
Jun 17, 2022
Article
EU Orphan Drug Designation – overcoming regulatory challenges
Jul 20, 2022
Article
Three strategies for articulating a coherent product value story
Dec 18, 2021
Report
New Medicines, Novel Insights: Accelerating development of cell and gene therapies
May 22, 2023
Blog
Rachel Smith joins Parexel as Executive Director and Head of the Rare Disease, Center of Excellence
Aug 10, 2022
Related Insights
Blog
Unpacking NICE’s review of the HST routing criteria: implications for manufacturers
Oct 3, 2024
Blog
Accelerating Delivery and Patient Access to Rare Disease Treatments – Highlights from World Orphan Drug Congress
May 2, 2024
Podcast
Why Rare Disease Therapeutics Need Early Market Access Planning
Jan 4, 2023
Webinar
China's Market Approval Policy and Medical Insurance Payment System for Rare Disease
Jul 21, 2022
Report
New Medicines, Novel Insights: Advancing rare disease drug development
May 22, 2023
Article
How biotechs can strengthen their value story with advanced analytics
Feb 15, 2022
Blog
Pragmatic Trials: Targeting evidence generation to inform market access and meet payers’ needs
Feb 8, 2022
Blog
Parexel names first Patient Ambassador
Jun 17, 2022
Article
EU Orphan Drug Designation – overcoming regulatory challenges
Jul 20, 2022
Article
Three strategies for articulating a coherent product value story
Dec 18, 2021
Report
New Medicines, Novel Insights: Accelerating development of cell and gene therapies
May 22, 2023
Blog
Rachel Smith joins Parexel as Executive Director and Head of the Rare Disease, Center of Excellence
Aug 10, 2022